Original Article
CD4+ Invariant T-Cell–Receptor+ Natural Killer T Cells in Bronchial Asthma
N Engl J Med 2006; 354:1117-1129March 16, 2006
- Abstract
Background
Bronchial asthma is associated with an inflammatory process that is characterized by the presence in the airways of large numbers of CD4+ T cells producing interleukin-4 and interleukin-13. However, the CD4 antigen is expressed not only by class II major histocompatibility complex (MHC)–restricted CD4+ T cells, but also by a newly identified subgroup of T cells, CD1d-restricted natural killer T cells. These cells express a conserved (invariant) T-cell receptor and have a potent immunoregulatory function. Because mouse models of allergic asthma indicate that natural killer T cells are required for the development of allergen-induced airway hyperreactivity, we hypothesized that natural killer T cells play an important role in human asthma.
Methods
We used CD1d-tetramers, antibodies specific for natural killer T cells, as well as reverse-transcriptase–polymerase-chain-reaction analysis of the invariant T-cell receptor of natural killer T cells to assess the frequency and distribution of natural killer T cells in the lungs and in the circulating blood of 14 patients with asthma.
Results
About 60 percent of the pulmonary CD4+CD3+ cells in patients with moderate-to-severe persistent asthma were not class II MHC–restricted CD4+ T cells but, rather, natural killer T cells. The natural killer T cells expressed an invariant T-cell receptor and produced type 2 helper cytokines. In contrast, the CD4+ T cells found in the lungs of patients with sarcoidosis were conventional CD4+CD3+ T cells, not natural killer T cells.
Conclusions
Together with studies in mice indicating a requirement for natural killer T cells in the development of allergen-induced airway hyperreactivity, our results strongly suggest that CD4+ natural killer T cells play a prominent pathogenic role in human asthma.
Media in This Article
Figure 1
Analysis of CD4+ Cells in Bronchoalveolar-Lavage Fluid from Patients with Asthma (Panel A), Patients with Sarcoidosis (Panel B), and Controls (Panel C) for Expression of the Invariant T-Cell Receptor of Invariant Natural Killer T Cells.Figure 2
CD4+ Invariant Natural Killer T (NKT) Cells in the Airways of Patients with Asthma, but Not Patients with Sarcoidosis.Article Activity
- Article
Asthma is characterized by airway inflammation dominated by the presence of eosinophils and CD4+ T lymphocytes.1,2 The pulmonary CD4+ cells in patients with asthma produce predominantly the type 2 helper (Th2) cytokines interleukin-4, interleukin-5, and interleukin-13, which play essential roles in asthma by enhancing the growth, differentiation, and recruitment of eosinophils, basophils, mast cells, and IgE-producing B cells and by directly inducing airway hyperreactivity,3-5 a cardinal feature of asthma. Thus, class II major histocompatibility complex (MHC)–restricted CD4+ Th2 T cells, which have been detected in the airways of virtually all patients with asthma, are thought to play an essential role in the pathogenesis of bronchial asthma.6,7
The CD4 cell surface marker is expressed not only by conventional class II–restricted CD4+ T cells but also by natural killer T cells, a newly described, unique subgroup of lymphocytes that express features of both classic T cells and natural killer cells. In humans, natural killer T cells express CD4, CD8 (a small subgroup), or neither (i.e., negative for both CD4 and CD8 surface markers, also called double-negative cells). Many natural killer T cells express a highly restricted repertoire of T-cell receptors consisting of Vα14-Jα18 (in mice) and Vα24-Jα18 (in humans) and are called invariant T-cell receptor–positive natural killer T cells (invariant natural killer T cells).8 This T-cell receptor endows invariant natural killer T cells with the unique property of responding to glycolipid antigens, rather than peptide antigens presented by the nonpolymorphic class I MHC–like protein CD1d, expressed on antigen-presenting cells. Furthermore, on activation, invariant natural killer T cells rapidly produce large quantities of both type 1 helper (Th1)–biased (interferon-γ) and Th2-biased cytokines (interleukin-4), which enhance the function of dendritic cells, natural killer cells, and B cells, as well as the function of conventional CD4+ and CD8+ T cells.9 This rapid production of cytokines by invariant natural killer T cells is a manifestation of innate-like immunity and provides invariant natural killer T cells with the capacity to link innate and adaptive immune responses and critically regulate adaptive immunity and a host of inflammatory diseases.10-16 However, the role of invariant natural killer T cells in humans is not completely understood. To investigate whether these invariant natural killer T cells have an important role in human asthma, we studied the frequency and distribution of CD1d-restricted invariant natural killer T cells in the lungs and peripheral blood of patients with persistent asthma.
Methods
Study Population
The panel on medical human subjects of Stanford University, the committee on clinical investigation of Children's Hospital Boston, and the internal review board of the Karolinska Institute in Stockholm approved the study, and written informed consent was obtained from the 25 patients enrolled. Of these, the 14 patients who had asthma were lifelong nonsmokers who had received a diagnosis of moderate-to-severe persistent asthma.
Study Procedures
All study patients and healthy controls underwent blood drawing and fiberoptic bronchoscopy. Before transoral fiberoptic bronchoscopy (BF-XT 20 or BF-IT 30 bronchoscope, Olympus) was performed, spirometry was performed (before and after the administration of albuterol) with the use of equipment and procedures that met the guidelines of the American Thoracic Society.17 Patients and controls were required to have a baseline forced expiratory volume in one second (FEV1) of more than 40 percent of the predicted value. For entry into the study, patients with asthma were required to have variable airflow obstruction as documented by a variability of more than 30 percent during serial recordings of the peak expiratory flow rate2 and had to demonstrate both an increase of 250 ml and an increase of 12.5 percent in FEV1 after treatment with inhaled albuterol. Transoral fiberoptic bronchoscopy was performed as previously described.17 Peripheral-blood mononuclear cells were obtained from whole blood from donors and was processed as described in the Supplementary Appendix (available with the full text of this article at www.nejm.org).
Statistical Analysis
The statistical analysis was performed with InStat software, version 3.05 (GraphPad). The data are reported as means ±SD. Comparisons among the four groups included in the study — patients with asthma treated with corticosteroids, those with asthma not treated with corticosteroids, those with sarcoidosis, and control subjects — were performed with the Kruskal–Wallis test, with the use of Dunn's method for multiple comparisons. P values of less than 0.05 were considered to indicate statistical significance.
Results
We studied 14 patients with moderate-to-severe persistent asthma, 6 controls, and 5 patients with sarcoidosis, a respiratory inflammatory disease in which large numbers of CD4+ Th1 cells are present in the lungs18,19 (Table 1Table 1
Characteristics of Patients with Asthma and Results of Radioallergosorbent Testing and Studies of Lung Function.). No patient who had asthma had had an exacerbation of the disease or had received oral corticosteroid therapy or theophylline within the three months before entry into the study. The four patients with asthma who had not received inhaled corticosteroids within three months or longer before entry into the study had a mean predicted FEV1 of 71 percent, indicating clinically significant asthma (Table 1). Patients with atopic asthma had higher serum total IgE levels (mean, 361 IU per milliliter) than both patients who did not have atopic asthma (mean, 53 IU per milliliter) and controls (mean, 21 IU per milliliter). Although patients with asthma who had received corticosteroids had a higher mean serum IgE level (mean, 331 IU per milliliter) than those with asthma not treated with corticosteroids (mean, 118 IU per milliliter), this difference was not significant.The six control subjects were all asymptomatic volunteers with normal lung function without evidence of variable airflow obstruction, according to serial peak-flow measures. The five patients with sarcoidosis had stage II disease (lymphadenopathy and parenchymal lung findings) with bilateral hilar lymphadenopathy with evidence of reticulonodular shadowing or pulmonary infiltrates on high-resolution computed tomography (thin sections, 1 mm thick) of the lung. No patient with sarcoidosis had a history of erythema nodosum. All five were white (race was determined by physicians in this study), and all had noncaseating granulomas on transbronchial biopsy with negative fungal and acid-fast smears and cultures. The average duration of disease in these patients was six months. None had received treatment with oral or inhaled corticosteroids or other immunosuppressive agents.
Bronchoalveolar Lavage Findings
When specimens of bronchoalveolar-lavage fluid obtained from all study patients and controls were examined for the presence of CD4+ cells, CD8+ cells, and invariant natural killer T cells, we expected and found a higher total cell count in specimens from patients with asthma or sarcoidosis than in those from controls (Table 2Table 2
Analysis of Cells in the Bronchoalveolar-Lavage Fluid.). We also noted an increase in the proportion of lymphocytes in patients with asthma (13 percent) and in patients with sarcoidosis (21 percent), as compared with controls (7 percent), but these differences did not reach significance. In both the asthma and sarcoidosis groups, the majority of lymphocytes were CD4+. We then examined the bronchoalveolar-lavage fluid for the presence of invariant natural killer T cells using CD1d tetramers loaded with α-galactosylceramide, which specifically bind to the invariant T-cell receptor of invariant natural killer T cells,20 and with the monoclonal antibody 6B11, which specifically recognizes the CDR3 region of the Vα24-Jα18 T-cell receptor of human invariant natural killer T cells.21 Both reagents stained a large number of cells in the bronchoalveolar-lavage fluid obtained from patients with asthma, indicating that invariant natural killer T cells were present in the lungs of these patients (Figure 1 in the Supplementary Appendix). By contrast, virtually no invariant natural killer T cells were detectable in the bronchoalveolar-lavage fluid from either controls or patients with sarcoidosis.Because invariant natural killer T cells can express the CD4 cell surface marker, and because large numbers of CD4+ cells are known to be present in the lungs of patients with asthma, we measured the fraction of the CD4+ T cells in bronchoalveolar-lavage fluid of patients with asthma that were invariant natural killer T cells. Surprisingly, we found that a large fraction of these CD4+ T cells were invariant natural killer T cells. In patients with asthma, 45 to 86 percent (mean, 63 percent) of the CD4+ cells expressed the invariant T-cell receptor Vα24, as determined with the use of tetramer staining (Figure 1AFigure 1
Analysis of CD4+ Cells in Bronchoalveolar-Lavage Fluid from Patients with Asthma (Panel A), Patients with Sarcoidosis (Panel B), and Controls (Panel C) for Expression of the Invariant T-Cell Receptor of Invariant Natural Killer T Cells., and Table 2 in the Supplementary Appendix), whereas in patients with sarcoidosis (Figure 1B) and controls (Figure 1C), less than 1 percent of the CD4+ cells expressed the invariant T-cell receptor Vα24.Similar results were obtained with the use of direct immunofluorescence and confocal laser scanning microscopy of biopsy specimens from patients with asthma (Figure 2A through 2DFigure 2
CD4+ Invariant Natural Killer T (NKT) Cells in the Airways of Patients with Asthma, but Not Patients with Sarcoidosis.). A photomicrograph of one biopsy specimen (Figure 2A) shows the typical features of bronchial asthma — thickening of the basement membrane (lamina reticularis), epithelial disruption, and the presence of a mononuclear cell infiltrate, including invariant natural killer T cells, in the submucosa (lamina propria). In findings on confocal laser microscopy (Figure 2B), nearly all the lymphocytes in the lamina propria express both CD4 and the invariant T cell receptor Vα24; in contrast, in patients with sarcoidosis, the lymphocytes express CD4 but not Vα24 and therefore are not invariant natural killer T cells (Figure 2C).Analysis of the bronchoalveolar-lavage fluid obtained from patients with asthma indicated that 58 to 86 percent (mean, 74 percent) of the CD3+ cells were invariant natural killer T cells (Figure 2D), whereas in patients with sarcoidosis, less than 2 percent of the CD3+ cells were invariant natural killer T cells (Figure 2D, and Table 2 in the Supplementary Appendix). The number of invariant natural killer T cells in the lungs of the 14 patients with asthma did not appear to be significantly reduced with inhaled corticosteroid therapy: 10 of these patients had been treated with potent inhaled corticosteroids for six months or longer before they underwent bronchoscopy, yet the majority of the pulmonary CD3+ cells from the patients (Patients 1, 2, 3, 4, 8, 9, and 10) (Figure 2D) expressed the invariant T-cell receptor of invariant natural killer T cells, a finding similar to that observed in patients who had not been treated with corticosteroids (Patients 11, 12, 13, and 14).
To confirm the results of our study performed with the use of CD1d tetramers and the natural killer T-cell–specific antibody, we also performed semiquantitative reverse-transcriptase–polymerase-chain-reaction analysis. This molecular analysis demonstrated a high expression of the messenger RNA (mRNA) for the invariant T-cell receptor of invariant natural killer T cells in the lungs of patients with asthma. The mRNA for Vα24 and Vβ11 (the invariant T-cell receptor of natural killer T cells), but not Vα23 (an irrelevant T-cell receptor), was strongly expressed in cells from the bronchoalveolar-lavage fluid from patients with asthma (Figure 3Figure 3
Messenger RNA for the Invariant T-Cell Receptor of Invariant Natural Killer T (NKT) Cells Expressed in Cells Obtained by Bronchoalveolar-Lavage from Patients with Asthma.), but not in those from patients with sarcoidosis or controls. Together, these studies conducted with several different approaches indicate that CD4+ invariant natural killer T cells are virtually absent from the lungs of controls and patients with sarcoidosis but are present in high numbers in the lungs of patients with asthma.Although the invariant natural killer T cells in the lungs of patients with asthma were distinct from conventional class II–restricted CD4+ T cells in expressing an invariant T-cell receptor, the invariant natural killer T cells were similar to CD4+ Th2 cells in producing interleukin-4 and interleukin-13. We found that the invariant natural killer T cells in the lungs of patients with asthma produced both interleukin-4 and interleukin-13 but little interferon-γ on intracellular cytokine staining after activation with phorbol myristyl acetate and ionomycin (Figure 4AFigure 4
Expression of Interleukin-4, Interleukin-13, and Interferon-γ by Invariant Natural Killer (NKT) T Cells in Bronchoalveolar-Lavage Fluid and Peripheral Blood.) or by measurement of cytokines in supernatants after activation with α-galactosylceramide, which specifically activates invariant natural killer T cells (Figure 4B). In contrast, invariant natural killer T cells in the peripheral blood of all the patients with asthma or sarcoidosis and the controls produced all three cytokines (Figure 4C). Furthermore, in the bronchoalveolar-lavage fluid of patients with asthma, the vast majority (>95 percent) of the invariant natural killer T cells coexpressed CD4+ (Figure 4D), whereas in the peripheral blood of the patients with sarcoidosis and controls, only about 40 percent of the invariant natural killer T cells were CD4+ cells (approximately 50 percent of the invariant natural killer T cells were negative for both CD4 and CD8, and approximately 3 percent were CD8+) (Figure 4E). These results suggest that one subgroup of invariant natural killer T cells (those producing Th2 cytokines and expressing CD4) is selectively recruited or expanded in the lungs of patients with bronchial asthma but not in the lungs of patients with sarcoidosis.Discussion
Our studies show that CD4+ and CD3+ invariant natural killer T cells are abundant in the lungs of patients with chronic asthma but are virtually absent from the lungs of controls and patients with sarcoidosis. We confirmed previous work6,7 showing that T cells in the lungs of patients with asthma expressed the CD4 cell surface marker and produced Th2 cytokines, interleukin-4 and interleukin-13, but not interferon-γ — that is, that these T cells have the typical cytokine profile of conventional CD4+ Th2 lymphocytes. However, we showed that a great proportion (63 percent) of the pulmonary CD4+ T cells in patients with moderate-to-severe persistent asthma (and 73 percent of the CD3+ cells) expressed an invariant T-cell receptor and thus are invariant natural killer T cells, rather than conventional Th2 lymphocytes. The profusion of pulmonary invariant natural killer T cells in patients with asthma that we detected is surprising, but this finding mirrors those in mouse models of allergic asthma showing an essential role for invariant natural killer T cells in the development of allergen-induced airway hyperreactivity.15,16 Moreover, it is surprising that invariant natural killer T cells are present in the lungs of patients with asthma but not in the lungs of patients with sarcoidosis, a multisystem disorder predominantly involving the lungs. Both patients with sarcoidosis and those with asthma have large numbers of CD4+ T cells in their lungs, but in patients with asthma the T cells secrete interleukin-4 and interleukin-13, whereas in patients with sarcoidosis the T cells secrete interferon-γ rather than interleukin-4 and interleukin-13.22,23
The large number of invariant natural killer T cells in the lungs of patients with asthma is striking, especially given the fact that these cells constitute less than 0.1 percent of the mononuclear cells and less than 1 percent of the CD4+ T cells in the peripheral blood.24 In addition, our finding that more than 90 percent of the invariant natural killer T cells in the lungs of patients with asthma are CD4+ cells, whereas only about 50 percent of the invariant natural killer T cells in the peripheral blood are CD4+ cells, suggests that a subgroup of invariant natural killer T cells is recruited and enriched in the lung, leading to levels in the lung that are 100 times the levels in the peripheral blood. The preferential recruitment of invariant natural killer T cells may be related to a differential expression of chemokine receptors on the subgroup of CD4+ cells that are invariant natural killer T cells — a subgroup thought preferentially to produce interleukin-4 and interleukin-13.25-28 Accordingly, our study indicates that the immunology of asthma must be studied not by the examination of peripheral blood but, rather, by the evaluation of cells from within the lung. This principle may also hold true for other diseases in which invariant natural killer T cells have been reported to play an important role.
To identify invariant natural killer T cells, we used CD1d tetramers loaded with α-galactosylceramide, monoclonal antibody 6B11, or both, currently considered the most sensitive and specific reagents for detecting invariant natural killer T cells. We found that other reagents, such as antibody to the T-cell receptors Vα24 and Vβ11, although effective in identifying resting invariant natural killer T cells in peripheral blood, were less sensitive than CD1d tetramers and monoclonal antibody 6B11 in detecting invariant natural killer T cells in bronchoalveolar-lavage fluid. This finding might be due to the fact that the invariant natural killer T cells in the lungs of patients with asthma are partially activated, even in stable asthma, and that the T-cell–receptor expression on invariant natural killer T cells is greatly down-regulated after the activation of invariant natural killer T cells.29 However, levels of Vα24 and Vβ11 mRNA were highly expressed in cells in bronchoalveolar-lavage fluid (Figure 3), a finding consistent with the idea that T-cell receptor down-regulation reduces the sensitivity of detection of invariant natural killer T cells with anti-Vα24 and anti-Vβ11 antibody. We cannot exclude the possibility that even with the use of CD1d tetramers, monoclonal antibody 6B11, or both to identify invariant natural killer T cells in bronchoalveolar-lavage fluid, the frequency of invariant natural killer T cells in the lungs of patients with asthma might be underestimated because of T-cell receptor down-regulation.
CD4+ invariant natural killer T cells in the lungs of patients with asthma express an invariant T-cell receptor that recognizes glycolipid antigens that are now being defined.30 These antigens appear to be highly conserved in mice and humans and include the synthetic glycolipid α-galactosylceramide, the self-glycolipid isoglobotrihexosylceramide (iGb3),31,32 bacterial glycosphingolipids,33,34 and glycolipids from plant pollens.35 However, we propose that self-glycolipids such as iGb3, which may be exposed in the lungs as a result of pulmonary inflammation or lung injury, can activate invariant natural killer T cells, leading to airway inflammation and asthma. Alternatively, exogenous glycolipids, such as those from inhaled plant pollens, may activate invariant natural killer T cells in the lungs and cause asthma. Identifying the glycolipids recognized by the invariant T-cell receptor of natural killer T cells, and understanding the processes by which glycolipids are generated and activate invariant natural killer T cells, will probably provide important insights into asthma pathogenesis and perhaps reveal a host of new pathways amenable to new treatments specifically for asthma.
In summary, we found that a large fraction of the CD4+ T cells in the lungs of patients with asthma, but not in the lungs of patients with sarcoidosis, express the invariant T-cell receptor of invariant natural killer T cells, a newly described subgroup of T cells with immunoregulatory function. Together with studies in mice indicating the requirement of invariant natural killer T cells for the development of allergen-induced airway hyperreactivity, our results strongly suggest that invariant natural killer T cells in asthma represent a new paradigm in which CD4+ invariant natural killer T cells, in concert with conventional CD4+ T cells, produce interleukin-4 and interleukin-13, driving the development of inflammation in bronchial asthma. If invariant natural killer T cells do indeed play a prominent role in the pathogenesis of asthma, therapies for asthma that target pulmonary invariant natural killer T cells may be highly effective.
Supported by grants from the National Institutes of Health (PO1AI054456, RO1 AI26322, and R01 HL69507, to Dr. Umetsu; RO1 CA52511, to Dr. Kronenberg; and MO1-RR00070, to the Stanford University Medical Center General Clinical Research Center), the American Lung Association of California (to Dr. Akbari), and the Swedish Heart–Lung Foundation (to Dr. Wahlström).
Dr. Umetsu reports having received consulting fees from Telos Pharmaceuticals and owning equity in Innate Immunity. Dr. Faul reports having received consulting fees and lecture fees from Merck, Pfizer, GlaxoSmithKline, and Boehringer Ingelheim and research support from Merck; and Dr. DeKruyff, consulting fees from Telos Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.
Drs. Akbari and Faul contributed equally to this article.
We are indebted to Maria Wikén for performing some of the staining; to the tetramer facility at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, for providing CD1d tetramers; and to Mark Exley for providing invaluable reagents.
Source Information
From the Division of Immunology, Children's Hospital Boston, and the Department of Pediatrics, Harvard Medical School — both in Boston (O.A., R.H.D., D.T.U.); the Division of Pulmonary and Critical Care, Department of Medicine (J.L.F.), the Department of Pediatrics (E.G.H., D.T.U.), and the Department of Pathology (G.J.B.), Stanford University, Stanford, Calif.; the Division of Respiratory Medicine and Department of Medicine, Karolinska Institute, Stockholm (J.W.); and the Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, Calif. (M.K.).
Address reprint requests to Dr. Umetsu at the Division of Immunology, Children's Hospital Boston, Harvard Medical School, Karp Research Laboratories, 1 Blackfan Cir., Rm. 10127, Boston, MA 02115, or at dale.umetsu@childrens.harvard.edu.
- References
References
1
Busse WW ,Lemanske RF Jr . Asthma. N Engl J Med 2001;344:350-362
Full Text | Web of Science | Medline2
Faul JL ,Demers EA ,Burke CM ,Poulter LW . The reproducibility of repeat measures of airway inflammation in stable atopic asthma. Am J Respir Crit Care Med 1999;160:1457-1461
Web of Science | Medline3
Holt PG ,Macaubas C ,Stumbles PA ,Sly PD . The role of allergy in the development of asthma. Nature 1999;402:Suppl:B12-B17
CrossRef | Web of Science | Medline4
Grunig G ,Warnock M ,Wakil AE , et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263
CrossRef | Web of Science | Medline5
Wills-Karp M ,Luyimbazi J ,Xu X , et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261
CrossRef | Web of Science | Medline6
Robinson DS ,Hamid Q ,Ying S , et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304
Full Text | Web of Science | Medline7
Cohn L ,Elias JA ,Chupp GL . Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004;22:789-815
CrossRef | Web of Science | Medline8
Taniguchi M ,Harada M ,Kojo S ,Nakayama T ,Wakao H . The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513
CrossRef | Web of Science | Medline9
Kronenberg M ,Gapin L . The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-568
Web of Science | Medline10
Heller F ,Fuss IJ ,Nieuwenhuis EE ,Blumberg RS ,Strober W . Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-638
CrossRef | Web of Science | Medline11
Nieuwenhuis EE ,Matsumoto T ,Exley M , et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002;8:588-593
CrossRef | Web of Science | Medline12
Terabe M ,Matsui S ,Noben-Trauth N , et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-520
CrossRef | Web of Science | Medline13
Cui J ,Shin T ,Kawano T , et al. Requirement for V alpha 14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-1626
CrossRef | Web of Science | Medline14
Wang B ,Geng YB ,Wang CR . CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001;194:313-320
CrossRef | Web of Science | Medline15
Akbari O ,Stock P ,Meyer E , et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003;9:582-588
CrossRef | Web of Science | Medline16
Lisbonne M ,Diem S ,de Castro Keller A , et al. Cutting edge: invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol 2003;171:1637-1641
Web of Science | Medline17
Djukanovic R ,Wilson JW ,Lai CK ,Holgate ST ,Howarth PH . The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am Rev Respir Dis 1991;143:772-777
Web of Science | Medline18
Wahlstrom J ,Katchar K ,Wigzell H ,Olerup O ,Eklund A ,Grunewald J . Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 2001;163:115-121
Web of Science | Medline19
Agostini C ,Meneghin A ,Semenzato G . T-lymphocytes and cytokines in sarcoidosis. Curr Opin Pulm Med 2002;8:435-440
CrossRef | Web of Science | Medline20
Sidobre S ,Kronenberg M . CD1 tetramers: a powerful tool for the analysis of glycolipid-reactive T cells. J Immunol Methods 2002;268:107-121
CrossRef | Web of Science | Medline21
Tahir SM ,Cheng O ,Shaulov A , et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-4050
Web of Science | Medline22
Shigehara K ,Shijubo N ,Ohmichi M , et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001;166:642-649
Web of Science | Medline23
Ziegenhagen MW ,Muller-Quernheim J . The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253:18-30
CrossRef | Web of Science | Medline24
Lee PT ,Putnam A ,Benlagha K ,Teyton L ,Gottlieb PA ,Bendelac A . Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002;110:793-800
Web of Science | Medline25
Gumperz JE ,Miyake S ,Yamamura T ,Brenner MB . Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-636
CrossRef | Web of Science | Medline26
Lee PT ,Benlagha K ,Teyton L ,Bendelac A . Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002;195:637-641
CrossRef | Web of Science | Medline27
Kim CH ,Johnston B ,Butcher EC . Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002;100:11-16
CrossRef | Web of Science | Medline28
Sen Y ,Yongyi B ,Yuling H , et al. V alpha 24-invariant NKT cells from patients with allergic asthma express CCR9 at high frequency and induce Th2 bias of CD3+ T cells upon CD226 engagement. J Immunol 2005;175:4914-4926
Web of Science | Medline29
Crowe NY ,Uldrich AP ,Kyparissoudis K , et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003;171:4020-4027
Web of Science | Medline30
Brigl M ,Brenner MB . CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-890
CrossRef | Web of Science | Medline31
Naidenko OV ,Maher JK ,Ernst WA ,Sakai T ,Modlin RL ,Kronenberg M . Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med 1999;190:1069-1080
CrossRef | Web of Science | Medline32
Zhou D ,Mattner J ,Cantu C III , et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-1789
CrossRef | Web of Science | Medline33
Kinjo Y ,Wu D ,Kim G , et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-525
CrossRef | Web of Science | Medline34
Mattner J ,DeBord KL ,Ismail N , et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525-529
CrossRef | Web of Science | Medline35
Agea E ,Russano A ,Bistoni O , et al. Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med 2005;202:295-308
CrossRef | Web of Science | Medline
- Citing Articles (135)
Citing Articles
1
Young-Il Koh, Jae-Uoong Shim, Jeongook Wi, Yong Eun Kwon. (2012) The Role of Natural Killer T Cells in the Pathogenesis of Acute Exacerbation of Human Asthma. International Archives of Allergy and Immunology 158:2, 131-141
CrossRef2
Ariana Murata, Patrick M. Ling. (2011) Asthma Diagnosis and Management. Emergency Medicine Clinics of North America
CrossRef3
Tracey L. Bonfield, Kristie R. Ross. (2011) Asthma heterogeneity and therapeutic options from the clinic to the bench. Current Opinion in Allergy and Clinical Immunology1
CrossRef4
Matija Rijavec, Sinisa Volarevic, Katarina Osolnik, Mitja Kosnik, Peter Korosec. (2011) Natural killer T cells in pulmonary disorders. Respiratory Medicine 105, S20-S25
CrossRef5
Edit Gyimesi, Georgina Nagy, Éva Remenyik, Sándor Sipka, Margit Zeher, Tamás Bíró, Andrea Szegedi. (2011) Altered Peripheral Invariant Natural Killer T Cells in Atopic Dermatitis. Journal of Clinical Immunology 31:5, 864-872
CrossRef6
Jeff J Subleski, Qun Jiang, Jonathan M Weiss, Robert H Wiltrout. (2011) The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 3:10, 1167-1184
CrossRef7
S. T. Scanlon, S. Y. Thomas, C. M. Ferreira, L. Bai, T. Krausz, P. B. Savage, A. Bendelac. (2011) Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. Journal of Experimental Medicine 208:10, 2113-2124
CrossRef8
Jeong-Hyun Kim, Byung-Lae Park, Charisse Flerida A Pasaje, Joon Seol Bae, Jong Sook Park, Sung Woo Park, Soo-Taek Uh, Mi-Kyeong Kim, Inseon S Choi, Sang Heon Cho, Byoung Whui Choi, Choon-Sik Park, Hyoung Doo Shin. (2011) Genetic association analysis of TAP1 and TAP2 polymorphisms with aspirin exacerbated respiratory disease and its FEV1 decline. Journal of Human Genetics 56:9, 652-659
CrossRef9
Marsha Wills-karp. 2011. Role of Th2 Cells in the Allergic Diathesis. , 15-25.
CrossRef10
Lanny J. Rosenwasser. (2011) Current Understanding of the Pathophysiology of Allergic Rhinitis. Immunology and Allergy Clinics of North America 31:3, 433-439
CrossRef11
Karine Botturi, Marie Langelot, David Lair, Anaïs Pipet, Mallory Pain, Julie Chesne, Dorian Hassoun, Yannick Lacoeuille, Arnaud Cavaillès, Antoine Magnan. (2011) Preventing asthma exacerbations: What are the targets?. Pharmacology & Therapeutics 131:1, 114-129
CrossRef12
Soma Jyonouchi, Valsamma Abraham, Jordan S. Orange, Jonathan M. Spergel, Laura Gober, Emily Dudek, Rushani Saltzman, Kim E. Nichols, Antonella Cianferoni. (2011) Invariant natural killer T cells from children with versus without food allergy exhibit differential responsiveness to milk-derived sphingomyelin. Journal of Allergy and Clinical Immunology 128:1, 102-109.e13
CrossRef13
G. Wingender, P. Rogers, G. Batzer, M. S. Lee, D. Bai, B. Pei, A. Khurana, M. Kronenberg, A. A. Horner. (2011) Invariant NKT cells are required for airway inflammation induced by environmental antigens. Journal of Experimental Medicine 208:6, 1151-1162
CrossRef14
D. Lai, J. Zhu, T. Wang, J. Hu-Li, M. Terabe, J. A. Berzofsky, C. Clayberger, A. M. Krensky. (2011) KLF13 sustains thymic memory-like CD8+ T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells. Journal of Experimental Medicine 208:5, 1093-1103
CrossRef15
Amjad Horani, David Shoseyov, Sarit Doron, Rufayda Mruwat, Johnny Amer, Eitan Kerem, Rifaat Safadi. (2011) Immune modulation of ovalbumin-induced lung injury in mice using β-glucosylceramide and a potential role of the liver. Immunobiology 216:5, 548-557
CrossRef16
Gourapura J. Renukaradhya, Cordelia Manickam, Mahesh Khatri, Abdul Rauf, Xiangming Li, Moriya Tsuji, Gireesh Rajashekara, Varun Dwivedi. (2011) Functional Invariant NKT Cells in Pig Lungs Regulate the Airway Hyperreactivity: A Potential Animal Model. Journal of Clinical Immunology 31:2, 228-239
CrossRef17
Chun Geun Lee, Carla A. Da Silva, Charles S. Dela Cruz, Farida Ahangari, Bing Ma, Min-Jong Kang, Chuan-Hua He, Seyedtaghi Takyar, Jack A. Elias. (2011) Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury. Annual Review of Physiology 73:1, 479-501
CrossRef18
Sergio D Rosenzweig. 2011. Primary Immunodeficiency Affecting the Innate Immune System. .
CrossRef19
Stuart P. Berzins, Mark J. Smyth, Alan G. Baxter. (2011) Presumed guilty: natural killer T cell defects and human disease. Nature Reviews Immunology 11:2, 131-142
CrossRef20
Ya-Jen Chang, Hye Young Kim, Lee A. Albacker, Hyun Hee Lee, Nicole Baumgarth, Shizuo Akira, Paul B. Savage, Shin Endo, Takashi Yamamura, Janneke Maaskant, Naoki Kitano, Abel Singh, Apoorva Bhatt, Gurdyal S. Besra, Peter van den Elzen, Ben Appelmelk, Richard W. Franck, Guangwu Chen, Rosemarie H. DeKruyff, Michio Shimamura, Petr Illarionov, Dale T. Umetsu. (2011) Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. Journal of Clinical Investigation 121:1, 57-69
CrossRef21
Chiaki Iwamura, Toshinori Nakayama. (2010) Role of NKT cells in allergic asthma. Current Opinion in Immunology 22:6, 807-813
CrossRef22
Douglas S. Robinson. (2010) The role of the T cell in asthma. Journal of Allergy and Clinical Immunology 126:6, 1081-1091
CrossRef23
Clare M. Lloyd, Edith M. Hessel. (2010) Functions of T cells in asthma: more than just TH2 cells. Nature Reviews Immunology 10:12, 838-848
CrossRef24
Ding Zhang, Jingwen Xia, Xiaodong Chen. (2010) Tendencias temporales de las concentraciones de citocinas Th1 y Th2 en esputo inducido de pacientes asmáticos durante infecciones víricas agudas de las vías respiratorias superiores. Archivos de Bronconeumología 46:9, 459-465
CrossRef25
Jenna R. Murdoch, Clare M. Lloyd. (2010) Chronic inflammation and asthma. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 690:1-2, 24-39
CrossRef26
Bassem G Chahine, Sami L Bahna. (2010) The role of the gut mucosal immunity in the development of tolerance versus development of allergy to food. Current Opinion in Allergy and Clinical Immunology 10:4, 394-399
CrossRef27
Wen Hao Wu, Chang Ook Park, Sang Ho Oh, Hee Jung Kim, Yeon Sook Kwon, Byung Gi Bae, Ji Yeon Noh, Kwang Hoon Lee. (2010) Thymic stromal lymphopoietin–activated invariant natural killer T cells trigger an innate allergic immune response in atopic dermatitis. Journal of Allergy and Clinical Immunology 126:2, 290-299.e4
CrossRef28
N. J. Reyes, E. Mayhew, P. W. Chen, J. Y. Niederkorn. (2010) NKT cells are necessary for maximal expression of allergic conjunctivitis1. International Immunology 22:8, 627-636
CrossRef29
A Bosco, S Ehteshami, D A Stern, F D Martinez. (2010) Decreased activation of inflammatory networks during acute asthma exacerbations is associated with chronic airflow obstruction. Mucosal Immunology 3:4, 399-409
CrossRef30
Seddon Y. Thomas, Yung H. Chyung, Andrew D. Luster. (2010) Natural killer T cells are not the predominant T cell in asthma and likely modulate, not cause, asthma. Journal of Allergy and Clinical Immunology 125:5, 980-984
CrossRef31
Y.-I. Koh, J.-U. Shim, J.-H. Lee, I.-J. Chung, J.-J. Min, J. H. Rhee, H. C. Lee, D. H. Chung, J.-O. Wi. (2010) Natural killer T cells are dispensable in the development of allergen-induced airway hyperresponsiveness, inflammation and remodelling in a mouse model of chronic asthma. Clinical & Experimental Immunologyno-no
CrossRef32
Nina Lane, R. Adrian Robins, Jonathan Corne, Lucy Fairclough. (2010) Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clinical Science 119:2, 75-86
CrossRef33
Peter Korosec, Matija Rijavec, Mira Silar, Izidor Kern, Mitja Kosnik, Katarina Osolnik. (2010) Deficiency of pulmonary Vα24 Vβ11 natural killer T cells in corticosteroid-naïve sarcoidosis patients. Respiratory Medicine 104:4, 571-577
CrossRef34
William E. Paul, Jinfang Zhu. (2010) How are TH2-type immune responses initiated and amplified?. Nature Reviews Immunology 10:4, 225-235
CrossRef35
S. Thunberg, G. Gafvelin, M. Nord, R. Grönneberg, J. Grunewald, A. Eklund, M. van Hage. (2010) Allergen provocation increases TH2-cytokines and FOXP3 expression in the asthmatic lung. Allergy 65:3, 311-318
CrossRef36
Young-Il Koh, Jae-Uoong Shim, Jeong-Ook Wi, Eui-Ryoung Han, Nam Chul Jin, Seul Hyun Oh, Cheol Kyu Park, Dong-Jin Park. (2010) Inverse association of peripheral blood CD4+ invariant natural killer T cells with atopy in human asthma. Human Immunology 71:2, 186-191
CrossRef37
Christina Vock, Hans-Peter Hauber, Michael Wegmann. (2010) The Other T Helper Cells in Asthma Pathogenesis. Journal of Allergy 2010, 1-14
CrossRef38
Gwang Cheon Jang. (2010) Natural killer T cell and pathophysiology of asthma. Korean Journal of Pediatrics 53:2, 136
CrossRef39
Loralyn A. Benoit, Michael J. Holtzman. (2010) New immune pathways from chronic post-viral lung disease. Annals of the New York Academy of Sciences 1183:1, 195-210
CrossRef40
Mirjam Belderbos, Ofer Levy, Louis Bont. (2009) Neonatal innate immunity in allergy development. Current Opinion in Pediatrics 21:6, 762-769
CrossRef41
D. Simon, E. Kozlowski, H.-U. Simon. (2009) Natural killer T cells expressing IFN-
and IL-4 in lesional skin of atopic eczema. Allergy 64:11, 1681-1684
CrossRef42
Milan Buc, Martin Dzurilla, Mojmir Vrlik, Maria Bucova. (2009) Immunopathogenesis of bronchial asthma. Archivum Immunologiae et Therapiae Experimentalis 57:5, 331-344
CrossRef43
Ponpan Matangkasombut, Rosemarie H. DeKruyff, Dale T. Umetsu. (2009) Reply. Journal of Allergy and Clinical Immunology 124:4, 862
CrossRef44
Nora A. Barrett, K. Frank Austen. (2009) Innate Cells and T Helper 2 Cell Immunity in Airway Inflammation. Immunity 31:3, 425-437
CrossRef45
P Matangkasombut, M Pichavant, R H DeKruyff, D T Umetsu. (2009) Natural killer T cells and the regulation of asthma. Mucosal Immunology 2:5, 383-392
CrossRef46
Stephen T. Holgate, Donna E. Davies. (2009) Rethinking the Pathogenesis of Asthma. Immunity 31:3, 362-367
CrossRef47
Sara M. Lind, Carlotta Kuylenstierna, Markus Moll, Emilie D. Jordö, Ola Winqvist, Lena Lundeberg, Maria A. Karlsson, Maria T. Linder, Catharina Johansson, Annika Scheynius, Johan K. Sandberg, Mikael C. I. Karlsson. (2009) IL-18 skews the invariant NKT-cell population via autoreactive activation in atopic eczema. European Journal of Immunology 39:8, 2293-2301
CrossRef48
Faisal Ahmad, Jesse Roman. (2009) Treating refractory asthma with antibodies against IL-5: is it ready for prime time?. Expert Review of Respiratory Medicine 3:3, 227-230
CrossRef49
Michael Rock, Sandra Yoder, Aimee Hoskins, Wiktor Ajayi, James R. Sheller, Ryszard Dworski. (2009) Effect of allergen challenge on the percentage of natural killer T cells in patients with atopic asthma. Annals of Allergy, Asthma & Immunology 102:5, 432-437
CrossRef50
Barbara Watts. (2009) Outpatient management of asthma in children age 5-11 years: Guidelines for practice. Journal of the American Academy of Nurse Practitioners 21:5, 261-269
CrossRef51
Chiara Nembrini, Benjamin J. Marsland, Manfred Kopf. (2009) IL-17–producing T cells in lung immunity and inflammation. Journal of Allergy and Clinical Immunology 123:5, 986-994
CrossRef52
Ponpan Matangkasombut, Gautham Marigowda, Aaron Ervine, Luaie Idris, Muriel Pichavant, Hye Young Kim, Takahiro Yasumi, S. Brian Wilson, Rosemarie H. DeKruyff, John L. Faul, Elliot Israel, Omid Akbari, Dale T. Umetsu. (2009) Natural killer T cells in the lungs of patients with asthma. Journal of Allergy and Clinical Immunology 123:5, 1181-1185.e1
CrossRef53
Muriel Pichavant, Ponpan Matangkasombut, Rosemarie H DeKruyff, Dale T Umetsu. (2009) Natural killer T cells regulate the development of asthma. Expert Review of Clinical Immunology 5:3, 251-260
CrossRef54
Christiane Kunert-Keil, Udo Jeschke, Giles Simms, Michael Kasper. (2009) Increased expression of glycodelin mRNA and protein in rat lungs during ovalbumin-induced allergic airway inflammation. Histochemistry and Cell Biology 131:3, 383-390
CrossRef55
Philomena Arrenberg, Ramesh Halder, Vipin Kumar. (2009) Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. Journal of Cellular Physiology 218:2, 246-250
CrossRef56
Masakazu Ichinose. (2009) Differences of Inflammatory Mechanisms in Asthma and COPD. Allergology International 58:3, 307-313
CrossRef57
Yoshitaka Okamoto, Shigetoshi Horiguchi, Heizaburo Yamamoto, Syuji Yonekura, Toyoyuki Hanazawa. (2009) Present Situation of Cedar Pollinosis in Japan and its Immune Responses. Allergology International 58:2, 155-162
CrossRef58
Mohammad Fereidouni, Reza Farid Hosseini, Farahzad Jabbari Azad, Jason Schenkel, Abdolreza Varasteh, Mahmoud Mahmoudi. (2009) Frequency of circulating iNKT cells among Iranian healthy adults. Cytometry Part B: Clinical Cytometry 9999B, NA-NA
CrossRef59
Shin-ichiro FUJII. (2009) Immunological evaluation for CML and its possibility for an immunotherapy. Japanese Journal of Clinical Immunology 32:4, 231-241
CrossRef60
Padmaja Subbarao, Allan Becker, Jeffrey R Brook, Denise Daley, Piush J Mandhane, Gregory E Miller, Stuart E Turvey, Malcolm R Sears. (2009) Epidemiology of asthma: risk factors for development. Expert Review of Clinical Immunology 5:1, 77-95
CrossRef61
James G. Martin, Manuel G. Cosio. 2009. The Lymphocyte in Asthma and COPD. , 157-172.
CrossRef62
Peter J. Barnes, Jeffrey M. Drazen. 2009. Pathophysiology of Asthma. , 399-423.
CrossRef63
Djukanović, Ratko, Gadola, Stephan D., . (2008) Virus Infection, Asthma, and Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 359:19, 2062-2064
Full Text64
A. M. Russano, E. Agea, C. Casciari, F. M. de Benedictis, F. Spinozzi. (2008) Complementary roles for lipid and protein allergens in triggering innate and adaptive immune systems. Allergy 63:11, 1428-1437
CrossRef65
N. L. Korpi-Steiner, D. Sheerar, E. B. Puffer, C. Urben, J. Boyd, A. Guadarrama, K. Schell, L. C. Denlinger. (2008) Standardized method to minimize variability in a functional P2X 7 flow cytometric assay for a multi-center clinical trial. Cytometry Part B: Clinical Cytometry 74B:5, 319-329
CrossRef66
Eckard Hamelmann, Udo Herz, Pat Holt, Arne Host, Roger P. Lauener, Paolo M. Matricardi, Ulrich Wahn, Magnus Wickman. (2008) New visions for basic research and primary prevention of pediatric allergy: An iPAC summary and future trends. Pediatric Allergy and Immunology 19, 4-16
CrossRef67
Stephen J. Galli, Mindy Tsai, Adrian M. Piliponsky. (2008) The development of allergic inflammation. Nature 454:7203, 445-454
CrossRef68
R. L. Rabin, A. I. Levinson. (2008) The nexus between atopic disease and autoimmunity: a review of the epidemiological and mechanistic literature. Clinical & Experimental Immunology 153:1, 19-30
CrossRef69
Khoa D. Nguyen, Chris Vanichsarn, Kari C. Nadeau. (2008) Increased cytotoxicity of CD4 + invariant NKT cells against CD4 + CD25 hi CD127 lo/– regulatory T cells in allergic asthma. European Journal of Immunology 38:7, 2034-2045
CrossRef70
Sebastian Joyce, Luc Van Kaer. (2008) Lung NKT cell commotion takes your breath away. Nature Medicine 14:6, 609-610
CrossRef71
Mark A. Exley, Runhua Hou, Angela Shaulov, Elena Tonti, Paolo Dellabona, Giulia Casorati, Omid Akbari, H. Orhan Akman, Edward A. Greenfield, Jenny E. Gumperz, Jonathan E. Boyson, Steven P. Balk, S. Brian Wilson. (2008) Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR α-chain CDR3 loop. European Journal of Immunology 38:6, 1756-1766
CrossRef72
Edy Y Kim, John T Battaile, Anand C Patel, Yingjian You, Eugene Agapov, Mitchell H Grayson, Loralyn A Benoit, Derek E Byers, Yael Alevy, Jennifer Tucker, Suzanne Swanson, Rose Tidwell, Jeffrey W Tyner, Jeffrey D Morton, Mario Castro, Deepika Polineni, G Alexander Patterson, Reto A Schwendener, John D Allard, Gary Peltz, Michael J Holtzman. (2008) Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nature medicine 14:6, 633-640
CrossRef73
STEPHEN T. HOLGATE. (2008) Pathogenesis of Asthma. Clinical & Experimental Allergy 38:6, 872-897
CrossRef74
Elena Ambrosino, Jay A Berzofsky, Masaki Terabe. (2008) Regulation of tumor immunity: the role of NKT cells. Expert Opinion on Biological Therapy 8:6, 725-734
CrossRef75
Julia Rolf, Emma Berntman, Martin Stenström, Emma M.K. Smith, Robert Månsson, Hanna Stenstad, Tetsuya Yamagata, William Agace, Mikael Sigvardsson, Susanna L. Cardell. (2008) Molecular profiling reveals distinct functional attributes of CD1d-restricted natural killer (NK) T cell subsets. Molecular Immunology 45:9, 2607-2620
CrossRef76
Ponpan Matangkasombut, Muriel Pichavant, Takahiro Yasumi, Carrie Hendricks, Paul B. Savage, Rosemarie H. DeKruyff, Dale T. Umetsu. (2008) Direct activation of natural killer T cells induces airway hyperreactivity in nonhuman primates. Journal of Allergy and Clinical Immunology 121:5, 1287-1289
CrossRef77
Benjamin D. Medoff, Seddon Y. Thomas, Andrew D. Luster. (2008) T Cell Trafficking in Allergic Asthma: The Ins and Outs. Annual Review of Immunology 26:1, 205-232
CrossRef78
Philippe Stock, Omid Akbari. (2008) Recent advances in the role of NKT cells in allergic diseases and asthma. Current Allergy and Asthma Reports 8:2, 165-170
CrossRef79
Carlos J. Montoya, Juan C. Cataño, Zoraida Ramirez, Maria T. Rugeles, S. Brian Wilson, Alan L. Landay. (2008) Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clinical Immunology 127:1, 1-6
CrossRef80
Aric L. Gregson, Aki Hoji, Rajan Saggar, David J. Ross, Bernard M. Kubak, Beth D. Jamieson, S Samuel Weigt, Joseph P. Lynch, Abbas Ardehali, John A. Belperio, Otto O. Yang. (2008) Bronchoalveolar Immunologic Profile of Acute Human Lung Transplant Allograft Rejection. Transplantation 85:7, 1056-1059
CrossRef81
Eyal Reinstein, Yoseph A Mekori, Adam Mor. (2008) Autoimmunity and mast cell-related diseases. Expert Review of Clinical Immunology 4:2, 267-274
CrossRef82
Peter J. Barnes. (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology 8:3, 183-192
CrossRef83
M. Pichavant, S. Goya, E. H. Meyer, R. A. Johnston, H. Y. Kim, P. Matangkasombut, M. Zhu, Y. Iwakura, P. B. Savage, R. H. DeKruyff, S. A. Shore, D. T. Umetsu. (2008) Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. Journal of Experimental Medicine 205:2, 385-393
CrossRef84
Francesca Scordamaglia, Mirna Balsamo, Antonio Scordamaglia, Alessandro Moretta, Maria Cristina Mingari, Giorgio Walter Canonica, Lorenzo Moretta, Massimo Vitale. (2008) Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. Journal of Allergy and Clinical Immunology 121:2, 479-485
CrossRef85
Everett H. Meyer, Rosemarie H. DeKruyff, Dale T. Umetsu. (2008) T Cells and NKT Cells in the Pathogenesis of Asthma. Annual Review of Medicine 59:1, 281-292
CrossRef86
Patrick G. Holt, Deborah H. Strickland, Matthew E. Wikström, Frode L. Jahnsen. (2008) Regulation of immunological homeostasis in the respiratory tract. Nature Reviews Immunology 8:2, 142-152
CrossRef87
Emil J. Bardana, Anthony Montanaro. 2008. Occupational and environmental allergic disorders. , 725-736.
CrossRef88
John W. Upham, Stephen M. Stick, Yuben Moodley. 2008. Lung Cell Biology. , 35-43.
CrossRef89
Demin Li, Nan Chen, Andrew J. McMichael, Gavin R. Screaton, Xiao-Ning Xu. (2008) Generation and characterisation of CD1d tetramer produced by a lentiviral expression system. Journal of Immunological Methods 330:1-2, 57-63
CrossRef90
R Boyton. (2008) The role of natural killer T cells in lung inflammation. The Journal of Pathology 214:2, 276-282
CrossRef91
H. Yamamoto, Y. Okamoto, S. Horiguchi, N. Kunii, S. Yonekura, T. Nakayama. (2007) Detection of natural killer T cells in the sinus mucosa from asthmatics with chronic sinusitis. Allergy 62:12, 1451-1455
CrossRef92
Masaki Terabe, Jay A. Berzofsky. (2007) NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends in Immunology 28:11, 491-496
CrossRef93
N. A. Hanley. (2007) Bone marrow-derived cells and the vasculature in diabetes: from biomarker to treatment?. Diabetologia 50:10, 2033-2035
CrossRef94
Carlos J. Montoya, David Pollard, Jeffrey Martinson, Kumud Kumari, Clive Wasserfall, Candice B. Mulder, Maria T. Rugeles, Mark A. Atkinson, Alan L. Landay, S. Brian Wilson. (2007) Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122:1, 1-14
CrossRef95
Ramesh C. Halder, Carlos Aguilera, Igor Maricic, Vipin Kumar. (2007) Type II NKT cell–mediated anergy induction in type I NKT cells prevents inflammatory liver disease. Journal of Clinical Investigation 117:8, 2302-2312
CrossRef96
(2007) Invariant Natural Killer T Cells in Obstructive Pulmonary Diseases. New England Journal of Medicine 357:2, 193-195
Full Text97
C Palmqvist, A J Wardlaw, P Bradding. (2007) Chemokines and their receptors as potential targets for the treatment of asthma. British Journal of Pharmacology 151:6, 725-736
CrossRef98
Otto O. Yang, S. Brian Wilson, Lance E. Hultin, Roger Detels, Patricia M. Hultin, F. Javier Ibarrondo, Beth D. Jamieson. (2007) Delayed Reconstitution of CD4 + iNKT Cells after Effective HIV Type 1 Therapy. AIDS Research and Human Retroviruses 23:7, 913-922
CrossRef99
Samantha W. M. Lun, C. K. Wong, Fanny W. S. Ko, David S. C. Hui, Christopher W. K. Lam. (2007) Increased Expression of Plasma and CD4+ T Lymphocyte Costimulatory Molecule CD26 in Adult Patients with Allergic Asthma. Journal of Clinical Immunology 27:4, 430-437
CrossRef100
Emmanuel Tupin, Yuki Kinjo, Mitchell Kronenberg. (2007) The unique role of natural killer T cells in the response to microorganisms. Nature Reviews Microbiology 5:6, 405-417
CrossRef101
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Wechsler, Michael E., Shepard, Jo-Anne O., Mark, Eugene J., . (2007) Case 15-2007. New England Journal of Medicine 356:20, 2083-2091
Full Text102
Kugathasan Mutalithas, Joanne Croudace, Cristina Guillen, Salman Siddiqui, David Thickett, Andrew Wardlaw, David Lammas, Chris Brightling. (2007) Bronchoalveolar lavage invariant natural killer T cells are not increased in asthma. Journal of Allergy and Clinical Immunology 119:5, 1274-1276
CrossRef103
A. B. Kay, F. R. Ali, L. G. Heaney, F. Benyahia, C. P. C. Soh, H. Renz, T. H. Lee, M. Larché. (2007) Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics. Allergy 62:5, 495-503
CrossRef104
Ho, Ling-Pei, . (2007) Natural Killer T Cells in Asthma — Toward Increased Understanding. New England Journal of Medicine 356:14, 1466-1468
Full Text105
Vijayanand, Pandurangan, Seumois, Grégory, Pickard, Chris, Powell, Robert M., Angco, Gilbert, Sammut, David, Gadola, Stephan D., Friedmann, Peter S., Djukanović, Ratko, . (2007) Invariant Natural Killer T Cells in Asthma and Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 356:14, 1410-1422
Full Text106
Y. González-Hernández, S. Pedraza-Sánchez, V. Blandón-Vijil, B. E. del Río-Navarro, G. Vaughan, M. Moreno-Lafont, A. Escobar-Gutiérrez. (2007) Peripheral Blood CD161 + T Cells from Asthmatic Patients are Activated During Asthma Attack and Predominantly Produce IFN-?. Scandinavian Journal of Immunology 65:4, 368-375
CrossRef107
James Kiley, Robert Smith, Patricia Noel. (2007) Asthma phenotypes. Current Opinion in Internal Medicine 6:2, 196-200
CrossRef108
Albert Bendelac, Paul B. Savage, Luc Teyton. (2007) The Biology of NKT Cells. Annual Review of Immunology 25:1, 297-336
CrossRef109
Barbro N. Melgert, Anuradha Ray, Machteld N. Hylkema, Wim Timens, Dirkje S. Postma. (2007) Are there reasons why adult asthma is more common in females?. Current Allergy and Asthma Reports 7:2, 143-150
CrossRef110
John Colgan, Paul Rothman. (2007) Manipulation of signaling to control allergic inflammation. Current Opinion in Allergy and Clinical Immunology 7:1, 51-56
CrossRef111
Fabrizio Spinozzi, Steven A. Porcelli. (2007) Recognition of Lipids from Pollens by CD1-Restricted T Cells. Immunology and Allergy Clinics of North America 27:1, 79-92
CrossRef112
Judith A. Woodfolk. (2007) T-cell responses to allergens. Journal of Allergy and Clinical Immunology 119:2, 280-294
CrossRef113
Dale T. Umetsu, Everett H. Meyer, Rosemarie H. DeKruyff. (2007) Natural Killer T Cells Regulate the Development of Asthma. International Reviews of Immunology 26:1-2, 121-140
CrossRef114
N. E. McCarthy, H. A. Jones, N. A. Marks, R. J. Shiner, P. W. Ind, H. O. Al-Hassi, N. R. English, C. M. Murray, J. R. Lambert, S. C. Knight, A. J. Stagg. (2007) Inhaled allergen-driven CD1c up-regulation and enhanced antigen uptake by activated human respiratory-tract dendritic cells in atopic asthma. Clinical & Experimental Allergy 37:1, 72-82
CrossRef115
Jennifer L. Matsuda, Laurent Gapin. (2007) Does the Developmental Status of Vα14i NKT Cells Play a Role in Disease?. International Reviews of Immunology 26:1-2, 5-29
CrossRef116
Elizabeth A. Jacobsen, Sergei I. Ochkur, Nancy A. Lee, James J. Lee. (2007) Eosinophils and asthma. Current Allergy and Asthma Reports 7:1, 18-26
CrossRef117
Richard M Effros, Hari Nagaraj. (2007) Asthma: new developments concerning immune mechanisms, diagnosis and treatment. Current Opinion in Pulmonary Medicine 13:1, 37-43
CrossRef118
Sachiko Miyake, Takashi Yamamura. (2007) Therapeutic Potential of CD1d-Restricted Invariant Natural Killer T Cell–based Treatment for Autoimmune Diseases. International Reviews of Immunology 26:1-2, 73-94
CrossRef119
Shinji Oki, Sachiko Miyake. (2007) Invariant Natural Killer T (iNKT) Cells in Asthma: A Novel Insight into the Pathogenesis of Asthma and the Therapeutic Implication of Glycolipid Ligands for Allergic Diseases. Allergology International 56:1, 7-14
CrossRef120
Yuko Nagata, Hajime Kamijuku, Masaru Taniguchi, Steven Ziegler, Ken-ichiro Seino. (2007) Differential Role of Thymic Stromal Lymphopoietin in the Induction of Airway Hyperreactivity and Th2 Immune Response in Antigen-Induced Asthma with Respect to Natural Killer T Cell Function. International Archives of Allergy and Immunology 144:4, 305-314
CrossRef121
Dale T Umetsu, Rosemarie H DeKruyff. (2006) Immune dysregulation in asthma. Current Opinion in Immunology 18:6, 727-732
CrossRef122
Dale T. Umetsu, Rosemarie H. DeKruyff. (2006) A role for natural killer T cells in asthma. Nature Reviews Immunology 6:12, 953-958
CrossRef123
T. Kawayama, P. M. O'Byrne, R. M. Watson, K. J. Killian, M. Duong, M. Yoshida, G. M. Gauvreau. (2006) Effects of inhaled ciclesonide on circulating T-helper type 1/T-helper type 2 cells in atopic asthmatics after allergen challenge. Clinical & Experimental Allergy 36:11, 1417-1424
CrossRef124
Johan Grunewald, Anders Eklund, Jan Wahlström. (2006) CD4 + T cells in sarcoidosis: targets and tools. Expert Review of Clinical Immunology 2:6, 877-886
CrossRef125
J. Gutermuth, G. Kollisch, M. Bewersdorff, A. Braun, F. Alessandrini, T. Jakob. (2006) Immunology highlights at high altitude: review of the fourth EAACI-GA2LEN Davos Meeting. Allergy 61:10, 1197-1199
CrossRef126
Kurt G. Tournoy, Sharen Provoost, Chris Hove, Guy Joos. (2006) The role of immune tolerance in asthma pathogenesis. Current Allergy and Asthma Reports 6:5, 437-443
CrossRef127
Alexandre C. Motta, Antoon J.M. van Oosterhout. (2006) T cells in asthma: Lessons from mouse models. Drug Discovery Today: Disease Models 3:3, 199-204
CrossRef128
O. Akbari. (2006) The role of iNKT cells in development of bronchial asthma: a translational approach from animal models to human. Allergy 61:8, 962-968
CrossRef129
Anastasios Karadimitris, Scott Patterson, Emmanouil Spanoudakis. (2006) Natural killer T cells and haemopoiesis. British Journal of Haematology 134:3, 263-272
CrossRef130
D Branch Moody. (2006) TLR gateways to CD1 function. Nature Immunology 7:8, 811-817
CrossRef131
M. D. Chapman. (2006) And the winner is ... 20 years of excellence in research on allergic disease!. Allergy 61:8, 959-961
CrossRef132
(2006) Invariant Natural Killer T Cells in Bronchial Asthma. New England Journal of Medicine 354:24, 2613-2616
Full Text133
Olive Leavy. (2006) NKT cells have a role in human asthma. Nature Reviews Immunology 6:5, 340-341
CrossRef134
(2006) In Brief. Nature Reviews Drug Discovery 5:5, 376-376
CrossRef135
Kay, A. Barry, . (2006) Natural Killer T Cells and Asthma. New England Journal of Medicine 354:11, 1186-1188
Full Text
- Letters
